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ABSTRACT 
In an open trial, drug-resistant schizophrenics were treated with clozapine for sixteen weeks. The 
patients were rated on BPRS. I'AXSS, Side effects scale and Olobal Impression Scale at weeks 0. 9 and 16. 
. I batten of base-tine investigations were (tone, and hemogram was repeated at weekly intenals. Of the 
total 29 /HI!wills included. 25 completed the trial. The patients showed significant improvement on both 
UPRS and I'.I V.S'.V, although the improvement was more in initial weeks than between 9 and 16 weeks. The 
most common side effects observed were sedation, hypersal nation and tachycardia. Issues of response of 
clozapine on negative svmtoms and a longer duration of the drug therapy are discussed. 
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Clozapine is an atypical antipsychotic with 
superior efficacy in severely ill, treatment-resistant 
schizophrenics. It is a noncataleptogcnic agent (Cow-
ard et al.. 1990) with high affinity for D, and Dt 
receptors (Van Tol ct al.. 1991). besides having ac-
tion on 5TH, (Altar et al.. I98N) and 5TH„. sites 
(Canton et al.. 1990). 
Its efficacy in schizophrenia was clearly dem-
onstrated in earlier studies (Elbolm & Haggcrstrom. 
1974; Singer <t Law. 1974; lusliclier Cornelsscn <fc 
Fcrner. 1976). but it was withdrawn from the mar-
ket following reports of associated agranulocytosis 
(Idanpana-Hcikkle ct al.. 1977). a potentially life-
threatening side-effect. 
II was net until late eighties, that Kane et al. 
(1988) demonstrated the usefulness of clozapine in 
severely ill treatment resistant schizophrenics. This 
led to rejuvenation of inter, -u in the drug, and many 
studies, both of controlled iPickarct al.. 1992): and 
descriptive type (Melt/er et al.. 1990. Davies et al.. 
1991. Wilson. 1992) were published. These studies 
gave clozapine a solid standing in the treatment of 
schizophrenic patients who were resistant to con-
ventional neuroleptics. 
With clozapine being prescribed more frc 
quently. although not regularly to even schizo-
phrenic patient, further issues opened up. One such 
point of debate was its ability to ameliorate negative 
symptoms. The drug was seen to have an unequivo-
cal effective resoponse on positive symptoms, and 
some studies also reported improvement in the nega-
tive symptoms. But what was not clear in these stud-
ies was that whether it were the primary or second-
ary negative symptoms that responded. As these stud-
ies also reported diminution in positive and extrapy-
ramidal symptoms, this possibh could have led to a 
secondary improvement in the negative s>niptoms. 
rather than being a direct action of the drug. Ad-
dressing this issue. Brier ct al (1994) in a double 
blind study of clozapine and haloperidol concluded 
that the former drug was comparatively superior in 
treating negative symptom, although this effect was 
relatively minor. However, as haloperidol itself is 
known to have propensity for producing extrapyra-
midal symptoms, this conclusion docs not seem to 
be very convincing. Other studies that support its 
efficacy in ameliorating the negative s> mploins have 
also been published (Mclt/cr ct al.. 19X9; Picker et 
al.. 1992; Clozapine Study Group. 1993 . Miller et 
al.. 1994) while oihers have refuted this finding 
(Brier eta).. 1994; Conlcyetal.. 1994). Carpenter et 
al. (1995) *' are profoundly con.nutted to 
the idea that the deficit ^tatc is enduring and that no 
treatment yet available can provide effective relief." 
(cited in Mcltzer. I'95). 
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Thus the present study was undertaken to 
evaluate the efficacy of clozapine in an open trial in 
schizophrenic patients who were non-responsive to 
the classical antipsychotics. 
MATERIAL AND METHOD 
In an open, non-comparative and non-cross-
over study schizophrenics were taken up for a 16 
week trial. The cases sclectecd were either chronic 
schizophrenics, acutely relapsed schizophrenics, or 
chronic schizophrenics with exacerbation. The di-
agnosis of schizophrenia was made according to ICD-
10 (WHO. 1992). All the patients had already been 
treated in vain with at least two neuroleptics chosen 
from chlorpromazinc (1000 mg/day or more), 
halopcridol or trifluoperazine in dose equivalents of 
1000 mg/day or more of chlorpromazinc. These drugs 
had already been tried for a period of at least six 
weeks in the past. 
All the patients were rated on the following 
instruments by one of the authors (MS) 
1. Brief Psychiatric Rating Scale (BPRS) (Overall 
& Gorham. 1962) at weeks 0,9. and 16. 
2. Positive and Negative Syndrome Scale (PANSS) 
(Kay ct al.. 1988) at weeks 0.9. and 16. 
3. Global Impression Scale at the beginning and 
end of the trial. 
4. Side-effects scale-weekly. 
5. Blood cell counts (Hb, TLC. DLC) - once weekly 
during the trial period and until 4 weeks later. 
6. Blood pressure, pulse and temperature were re-
corded at weekly intervals. 
All the patients were given a washout pe-
riod of one week who were on oral neuroleptics, and 
four weeks for depot preparations. The patients who 
were not receiving any neuroleptics at the time of 
intake in the trial were initiated on clozapine right 
away after baseline investigations were completed. 
The initial dose was 50 mg/day which was increased 
to 100 mg/day by the end of the first week. Incre-
ments were made in the dose as 100 mg/week to 
achieve a daily dose of 300 mg by the end of the 
fourth week. From fifth to sixteenth week the dose 
range was 300-450 mg/day depending upon the 
therapeutic response and/or the presence of side ef-
fects. 
The permitted concomitant medication was 
oral trihexyphenidyl for extrapyramidal symptoms, 
and nitrazepam for sleep. 
Baseline investigations comprised of SGOT. 
SGPT, ECG, serum creatinine, chest X-ra\. complete 
nomogram and urine analysis. 
A total leucocyte count below 3500/cmm or 
granulocyte count below 1500/cmm warranted cas-
sation of clozapine therapy. 
The total scores of BPRS and subscales of 
PANSS were compared at 9 and 16 weeks from the 
baseline. Paired Y test was employed to compare 
these ratings. The side-effect scores were calculated 
as the total percentage of patients exhibiting them. 
RESULTS 
A total of 29 patients, between the ages 18-40 
years, were included in the study, of which 4 dropped 
out for various reasons (seizures -1. GIT disturbance 
- 1. pyrexia -1 and intercurrent illness-1). Thus 25 
patients (18 males and 7 females) completed the 
study. The mean age of the patients and the duration 
of illness were 28.8±5.2 years and 7.3±4.2 years 
respectively. 
TABLE 1 
BPRS TOTAL SCORES 
WeekO 
Week 9 
Week 16 
MEAN 
40.76 
27.72 
23.20 
S.D 
12.50 
7.74' 
5.11" 
•Paired t-value = 17.53, d.f. = 24. (p<.00l) 
**Paircd t-value = 22.30, d.f. = 24. (p<.()01) 
The BPRS scores (Tabic 1), when compared 
from week 0 (40.8±12.5) showed improvement both 
at week 9 (27.7±7.7)and week 16 (23.2±5 1). which 
was highly significant statistically. 
The improvement on BPRS total scores is fur-
ther illustrated by the observation that by the end of 
9th week, of the 25 patients. 17(68%) had shown 
improvement upto 25%. By the end of trial i.e. 16 
weeks, the number had changed to 19(76%) in the 
26-50% group and 6(24%) in the 0-25% group. None 
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TABLE 2 
PERCENTAGE IMPROVEMENT FROM 
BASELINE TOTAL SCORES 
PERCENTAGE 
IMPROVEMENT 
0-25 
26-50 
Above 50 
9TH WEEK 
8 (32%) 
17(68%) 
Nil 
16TH WEEK 
6 (24%) 
19 (76%) 
Nil 
of the patients had improved beyond 50% as com-
pared to the baseline (Table2). 
The PANSS scores also showed similar im-
provement, but the results were more variegated. 
When compared from the baseline, at week 9 the 
scores for the positive and negative syndromes, and 
general psychopathology showed moderately signifi-
cant improvement (p<05) (Table 3), while for 
TABLE 3 
SCORES ON PANSS SUBSCALES 
MEASURES 
Positive 
Syndrome 
Negative 
Sydrome 
Composite 
Index 
General 
Psychopat-
hology 
WEEKO 
MEAN (S.D.) 
19.08 (6.82) 
20.08 (5.91) 
-0.28 (5.38) 
36.2(10.1) 
WEEK 9 
MEAN (S.D.) 
13.68(4.80)* 
13.80 (5.77)* 
0.08(5.72) 
25.64 (8.30) 
WEEK 16 
MEAN (S.D.) 
10.38(3.87) 
12.36(6.01) 
-2.24 (4.87) 
22.28 (5.97)* 
For all values d.f. = 24; *p<0.001 
TABLE 4 
SCORES ON PANSS MEASURES 
MEASURES 
Anergia 
Thought 
Disturbance 
Activation 
Paranoid/ 
Belligeience 
Depression 
WEEKO 
MEAN (S.D) 
10.8 (8.34) 
11.8(3.57) 
4.92 (2.17) 
9.00 (3.76) 
7.36 (4.13) 
WEEK 9 
MEAN (S.D.) 
6 52 (2 21)— 
8.84 (3.39)**' 
3.88(1.42)* 
5.8 (2.49)*** 
5.60 (2.28)"* 
WEEK 16 ' 
MEAN (S.D.) 
6.16(2.57)'" 
6 64 (3.34)**" 
3.64(1.26)** 
4.2 (1.49)"* 
4.92(1.83)" 
for all values d.f.=24 
*p>0.05, **p<0.01, ***p<0.001 
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TABLE 5 
SIDE EFFECTS AT END OF WEEKS 1,9,16 IN 
PATIENTS WHO COMPLETED STUDY (N=25) 
SIDE EFFECTS' 
1. Mild sedation 
2. Moderate 
sedation 
3. Severe sedation 
4. Mild hypersali-
vation 
5. Moderate hvpe-
rsalivation 
6. Severe hyper-
salivation 
7. Tachycardia 
8. Weight gain 
9. Constipation 
10. Tremors 
11. Hyperthermia 
12. Dizziness 
13. Hypotension 
WEEK1 
N(%) 
5(20) 
10(40) 
4(16) 
10(40) 
4(16) 
1(4) 
17(68) 
1(4) 
3(12) 
-
1(4) 
2(8) 
-
WEEK9 
N(%) 
8(32) 
3(12) 
2(8) 
12(48) 
1(4) 
1(4) 
12(48) 
1(4) 
5(20) 
1(4) 
2(8) 
-
-
WEEK16 
N(%) 
14 (56) 
7(28) 
1(4) 
7(28) 
1(4) 
-
15(60) 
3(12) 
4(16) 
4(16) 
-
-
3(12) 
anergia, thought disturbance and paranoid/belliger-
ence showed highly significant improvement 
(p<.001) (Table 4); for the rest of the subscales, the 
scores were significant at p<.01 level. 
At week 16, the trend for improvement on 
PANSS continued, but with little variation. Com-
pared to that at week 9, for the positive syndrome, 
negative syndrome, general psychopathology, 
anergia, thought disturbance and paranoid/belliger-
ence the improvement was similar, but that in acti-
vation was much more (p<.01), and for depression 
much less (p<.05), as compared to the other vari-
ables. 
The side-effect profile (Table 5) shows that the 
most frequently observed side-effect was tachycardia 
throughout the period of the trial (68% at week 1. 
48% at week 9. and 60% at week 16). followed by 
mild hvpersalivation (40%, 48% and 28% 
rcspectivly). Although a general trend seen was in 
diminution in the frequency of the observed side-
effects, but sedation (mild) showed an acclivity with 
the progression of the trial. Moderate sedation was 
maximally observed in the initial week, and severe A.K. AGARWAL et al. 
sedation, although present initially in only a few 
patients (16% at week 1), gradually diminished in 
frequency (8% and 4% at weeks 9 and 16 respec-
tively). 
A significant finding was that among the 4 
dropouts, none were due to hematological side-ef-
fect. 
DISCUSSION 
Ours was an open study in which the efficacy 
of clozapine was evaluated in patients of schizophre-
nia who had been labeled previously as chronic/re-
sistant or were intolerant to conventional 
neuroleptics. 
In our study the initial BPRS scores were quite 
high, and showed a steady diminution over the du-
ration of the trial. The improvement rated between 
weeks 9 and 16 was much more than that in the ini-
tial nine weeks. However, as the trial was terminated 
at this point, it cannot be commented whether this 
improvement would have accrued further or achieved 
a plateau. Other studies of longer duration have re-
ported that the benefits stablize in about 3-6 months 
time, after which no further benefit is seen 
(Lindstrom. 1988: Melt/.er. 1992 : BrieretaL 1993). 
However, this lime course of improvement seems not 
unique to clozapine, as Carpenter and colleagues 
(1995) have commented that a similar response time 
course is seen with the standard neuroleptic treat-
ment. 
In our study, clozapine was found to be effec-
tive against positive and negative symptoms both, 
as measured on PANSS. The changes in the nega-
tive symptoms, when compared from the baseline, 
were highly significant (Table 4), and the patients 
showed benefit on all the parameters. Other workers 
have shown a differential response on negative symp-
toms. 
While Kane et al. (1988) found that clozapine 
significantly reduced scores for emotional with-
drawal, blunted affect and psychomotor retardation, 
Meltzer ct al. (1989) have reported that affective flat-
tening and anhedonia does not respond to the drug. 
It has also been shown in some studies that the pri-
mary negative symptoms do not respond to clozapine 
(Conley et al.. 1994), but the drug is only of use in 
ameliorating the secondary negative symptoms. Brier 
et al. (1994) in a controlled study, found that the 
patients with primary negative symptoms responded 
poorly to clozapine, although it was beneficial in 
patients with non-deficit schizophrenia. In our study 
we did not differentiate between deficit and non-defi-
cit schizophrenia, neither covariated the significance 
of response in negative symptoms to the positive 
symptoms. 
Clozapine, initially introduced about 3 decades 
ago, was withdrawn from the market owing to re-
ports of agranuocytosis induced by it. Licberman et 
al. (1988) have cited a 2% cumulative incidence af-
ter 52 weeks of clozapine treatment for 
agranulocytosis. In our study none of the patients 
developed even leucopenia sufficient enough to stop 
the treatment. 
The other common side-effects observed in our 
study were sedation, hypersalivation. tachycardia, 
postural hypotension and dizziness (Table 5). Fitton 
& Heel (1990) have observed similar side-effects in 
as many as 40% of their of their patients. Brier at al. 
(1994) also found excessive salivation and 
tachycardia to be most frequently observed adverse 
effect, which is in close agreement with our find-
ings. 
This being one of the first studies in the coun-
try, we do not have other data to compare our find-
ings with the patients in this country. This initial 
study has shown the benefits of clozapine in chronic 
or treatment-resistant patients which argues favor-
ably for the drug. As it is a new drug for this coun-
try, and consequently, there not being much clinical 
experience with it, the clinicians should be cautious 
in using it. 
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